top of page

Malaysia’s MDA: HARMONISED CLASSIFICATION OFMEDICAL DEVICES IN ASEAN

Writer's picture: Sharan MuruganSharan Murugan

Association of Southeast Asian Nations, or ASEAN, is a political and economic union of 10 members states in Southeast Asia, which are Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam.

As part of its commitment to harmonizing risk classifications across the Association of Southeast Asian Nations (ASEAN), Malaysia's Medical Device Authority (MDA) has published a list of risk classifications for medical devices, including in-vitro diagnostics (IVDs).


The ASEAN Medical Device Directive (AMDD) aims to harmonize medical device regulations among ASEAN countries. On 23 April 2020, Malaysia signed this Agreement, which entered into force on 1 January 2015.


The purpose of this document is to provide guidance to manufacturers and authorised representatives regarding the risk classification of medical devices, including in-vitro diagnostic (IVD) medical devices which have been harmonised in ASEAN.


Based on their intended use/purpose, this guidance document provides the harmonised list of risk classifications for medical devices, including in-vitro diagnostic (IVD) medical devices.


Click on this LINK to know more about the list of harmonised risk classification of identified medical devices that are listed in Annex A of this guidance.





Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page